3 Top Diabetes Biotechs to Buy Into Right Now

Diabetes is huge problem for Americans. Between 1990 and 2010, the number of U.S. residents with diabetes tripled, and the number of new cases annually doubled. Both prevalence and costs associated with diabetes are projected to increase by more than 50% by 2030.

But where there's a problem, there's also an opportunity.

Back to news